To prescreen or not to prescreen for broadly neutralizing antibody sensitivity in HIV cure-related trials

The use of broadly neutralizing antibodies (bNAbs) as a cure-related research strategy for human immunodeficiency virus (HIV) has gained attention from the scientific community. bNAbs are specialized antibodies that target HIV-1 by binding to proteins on the surface of the virus, preventing the infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Hursch, Dubé, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491646/
https://www.ncbi.nlm.nih.gov/pubmed/37692548
http://dx.doi.org/10.1016/j.jve.2023.100339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491646/
https://www.ncbi.nlm.nih.gov/pubmed/37692548
http://dx.doi.org/10.1016/j.jve.2023.100339

Ejemplares similares